The FTO gene — officially the fat mass and obesity-associated gene — contains one of the most replicated loci in obesity genetics. Most research has focused on a cluster of intron-1 variants¹¹ intron-1 variants
The first non-coding interval of FTO, approximately 53,738,000–53,800,000 bp on chromosome 16 (GRCh38), contains the best-studied GWAS hits for obesity including rs9939609 and the causal variant rs1421085 led by rs9939609 and the mechanistic variant rs1421085. But the FTO gene spans over 400 kilobases across chromosome 16, harboring multiple intronic regions, and rs11644943 sits at a distinct chromosomal position²² distinct chromosomal position
chr16:53,961,672 (GRCh38) — approximately 200 kilobases downstream of the primary intron-1 obesity cluster, in a separate linkage disequilibrium block from the well-characterized FTO obesity haplotype.

The Mechanism

rs11644943 is an intronic FTO variant. Like all FTO intronic variants, it does not alter the amino acid sequence of the FTO protein — instead, it sits within a non-coding regulatory region where it may influence local chromatin accessibility, splicing efficiency, or transcriptional output of neighboring exons. The FTO protein itself functions as an N6-methyladenosine (m6A) RNA demethylase³³ N6-methyladenosine (m6A) RNA demethylase
m6A is the most abundant chemical modification on messenger RNA. FTO erases it, altering mRNA stability and translation of target genes including those involved in appetite regulation and adipocyte differentiation. Elevated FTO expression raises ghrelin mRNA stability (increasing hunger drive) and promotes white adipocyte differentiation over thermogenic beige adipocytes (reducing resting energy expenditure). The T allele at rs11644943 may act through a similar upregulatory mechanism on FTO transcript levels in relevant tissues, though the specific regulatory element disrupted by this variant has not been characterized.

Critically, the rs11644943 T allele and nearby rs7206790 are not in linkage disequilibrium with previously reported obesity-associated FTO variants⁴⁴ the rs11644943 T allele and nearby rs7206790 are not in linkage disequilibrium with previously reported obesity-associated FTO variants
Xu et al. 2014 (PMID:25251416) explicitly confirmed that rs11644943 and rs7206790 are independent of rs9939609 and other previously catalogued FTO GWAS hits in the Chinese school-age population studied. This makes rs11644943 a potentially independent FTO obesity signal — tagging genetic variation in a different part of the gene rather than serving as a proxy for the primary intron-1 cluster.

The Evidence

Published evidence for rs11644943 is limited. The primary study is a case-control analysis in Chinese school-age children⁵⁵ case-control analysis in Chinese school-age children
Xu et al. Rs7206790 and rs11644943 in FTO gene are associated with risk of obesity in Chinese school-age population. PLoS One 2014. PMID:25251416 (500 obese cases, 500 matched controls). The investigators identified the A allele as protective: carriers of the AA genotype had a substantially lower risk of obesity compared to T-allele carriers (adjusted OR 0.16, 95% CI 0.04–0.72). The association survived adjustment for age, sex, and residential location. When combined with rs9939609 in a three-SNP genetic risk score model, dose-response relationships with obesity were observed, though rs11644943's contribution was confirmed as independent of the primary FTO locus.

Direct evidence for rs11644943 outside this single study is not yet available in the peer-reviewed literature, and the variant is not catalogued in ClinVar or the GWAS Catalog. The evidence level is therefore emerging — the association requires replication in larger and ethnically diverse cohorts before it can be considered a confirmed independent FTO signal. For context, the broader FTO locus has strong, replicated evidence for influencing obesity risk across populations⁶⁶ strong, replicated evidence for influencing obesity risk across populations
Frayling et al. Science 2007. PMID:17434869, with the primary intron-1 signal explaining an additive ~3 kg difference in body weight per risk allele in Europeans.

Practical Actions

Because rs11644943 is an FTO intronic variant, the genotype-specific advice derives from what is known about the FTO pathway. Physical activity consistently attenuates FTO-related obesity risk: a meta-analysis of 218,166 adults⁷⁷ meta-analysis of 218,166 adults
Kilpeläinen et al. 2011. PMID:22069379 found that physically active individuals showed a 27% lower FTO allele-associated obesity effect than sedentary individuals — one of the largest known gene-environment interactions in common disease genetics. Dietary protein composition also matters: higher-protein meals improve satiety signaling in FTO risk allele carriers by compensating for impaired gut hormone (GLP-1, PYY) responses. These effects have been demonstrated across FTO intron variants generally, though not yet specifically for rs11644943.

Interactions

rs11644943 is not in LD with the primary FTO intron-1 obesity cluster (rs9939609, rs1421085, rs8050136), making it a potentially additive second FTO signal. Users who carry both the T allele at rs11644943 AND the A risk allele at rs9939609 may carry compounded FTO pathway burden through independent intronic regulatory mechanisms. The adjacent variant rs7206790 (chr16:53,763,996) was studied alongside rs11644943 in the Chinese school-age cohort but appears to be in a different intron and LD block; the two variants together may index distinct regulatory regions across the FTO gene body.

Your veins are not passive conduits. They are living structures whose walls depend on a continuous interplay of growth signals, smooth muscle tone, and extracellular matrix remodeling. VEGFA — vascular endothelial growth factor A¹¹ VEGFA — vascular endothelial growth factor A
the master regulator of angiogenesis; controls endothelial proliferation, vessel permeability, and vascular tone through binding to VEGFR1 and VEGFR2 — sits at the center of this balance. The rs11967262 variant lies approximately 7 kb upstream of the VEGFA gene on chromosome 6p21.1, in a region that likely influences VEGFA expression in vascular tissue. Carriers of the G allele show a small but reproducibly elevated risk of developing varicose veins.

Varicose veins affect an estimated 25% of women and 15% of men in Western populations, with heritability estimates ranging from 17–49%. They are not merely cosmetic — dilated, tortuous superficial veins reflect underlying venous hypertension and valve incompetence that, if unchecked, can progress to chronic venous insufficiency, venous ulceration, and superficial thrombophlebitis.

The Mechanism

VEGFA is significantly overexpressed in the walls of varicose veins compared to normal veins. This upregulation is now understood as both a cause and consequence of venous dysfunction. VEGFA is a potent inducer of vascular permeability — it loosens endothelial junctions, allows plasma proteins to leak into the vessel wall, and drives edema. In the venous context, chronically elevated VEGFA signaling through VEGFR2 promotes endothelial cell proliferation and smooth muscle cell phenotypic switching from contractile to synthetic state, weakening the structural integrity of the vein wall.

VEGFA also induces vasodilation through nitric oxide–dependent pathways, reducing venous tone. In the deep venous system this vasodilation is tightly regulated; but in the superficial venous system — which lacks surrounding muscle support — sustained VEGFA overactivity can tip the balance toward stasis, reduced return flow, and progressive dilation. Hypoxia and venous hypertension, which develop as veins dilate and valves fail, further upregulate VEGFA expression in a feed-forward loop.

The rs11967262 variant is intergenic at 6p21.1, ~7 kb upstream of the VEGFA transcription start site²² intergenic at 6p21.1, ~7 kb upstream of the VEGFA transcription start site
the exact regulatory element affected has not been functionally characterized; the association may act through eQTL effects on VEGFA expression in venous endothelial or smooth muscle cells, or through linkage disequilibrium with a causal variant in the VEGFA promoter region. The VEGFA gene has several known regulatory polymorphisms in its 5′ UTR (notably rs2010963) that alter expression levels, and rs11967262 may tag a similar effect.

The Evidence

The primary association evidence comes from the largest varicose vein GWAS published to date. Ahmed et al. 2022 in Nature Communications³³ Ahmed et al. 2022 in Nature Communications
two-stage analysis: 22,473 cases and 379,183 controls from UK Biobank; replication in 113,041 cases and 295,928 controls from 23andMe identified 49 genome-wide significant signals across 46 loci. The rs11967262 G allele reached a meta-analysis p-value of 1.45×10⁻¹⁹ with an odds ratio of 1.09 — a modest per-allele effect that is nonetheless very well-powered given the exceptional sample size.

The biological plausibility of the VEGFA locus is strong. The varicose vein wall consistently shows elevated VEGFR1, VEGFR2, and VEGFR3 expression compared to normal venous tissue, particularly in cases complicated by thrombophlebitis. Plasma VEGFA levels are significantly higher in varicose vein patients. A Mendelian randomization study⁴⁴ Mendelian randomization study
genetically instrumented VEGF levels examined as causal instrument in ~16,000 Europeans found that higher circulating VEGF levels associate with increased venous thromboembolism risk (OR 1.064, 95% CI 1.009–1.122), extending the causal inference beyond simple association.

A separate candidate gene study found the VEGFA promoter variant rs2010963 C allele to be protective against varicose veins⁵⁵ protective against varicose veins
case-control study of 448 patients and 609 controls in ethnic Russians; C allele OR 0.73, 95% CI 0.59–0.91, p=0.004, directly demonstrating that VEGFA regulatory variants influence varicose vein susceptibility in an allele-specific manner.

The OR of 1.09 per G allele is modest by clinical standards. The absolute risk increase for GG homozygotes compared to CC homozygotes is approximately 18–19% relative risk elevation — meaningful in context of a common, heritable condition but not deterministic. Most GG carriers will not develop clinically significant varicose veins if they manage modifiable risk factors aggressively.

Practical Actions

The VEGFA locus variant acts through venous wall biology — specifically vascular permeability, smooth muscle tone, and extracellular matrix remodeling. Interventions that reduce venous hydrostatic pressure, improve wall tone, and reduce conditions that upregulate VEGFA (hypoxia, venous stasis, inflammation) are directly relevant to this genotype.

Graduated compression garments (20–30 mmHg for prevention; 30–40 mmHg for established insufficiency) mechanically reduce the venous hypertension that drives VEGFA upregulation. Occupations requiring prolonged standing or sitting — which are the strongest modifiable risk factors for varicose veins independent of genetics — are particularly relevant for G allele carriers to mitigate.

Micronized purified flavonoid fractions (MPFF, e.g., diosmin-hesperidin combinations) have evidence from randomized trials for reducing venous edema and improving microcirculation in chronic venous disease. They act partly by reducing vascular permeability — a VEGFA-mediated mechanism — making them particularly relevant for VEGFA-pathway genotypes.

Interactions

The VEGFA locus interacts with other varicose vein risk loci identified in the same GWAS — including CASZ1 (vascular development), PIEZO1 (mechanosensitive ion channel), and extracellular matrix genes (ELN, LTBP3, COL3A1). Individuals carrying multiple risk alleles across these independent loci will have additive polygenic risk that compounds the modest VEGFA effect. The polygenic risk score derived in the Ahmed et al. 2022 cohort has predictive utility for varicose vein surgery, suggesting that cumulative genetic burden at VEGFA and these other loci has clinical prognostic value.

VEGFA also interacts with the coagulation cascade — elevated VEGFA increases vascular permeability that can promote local thrombus formation in venous stasis conditions. Carriers of thrombophilia variants (Factor V Leiden rs6025, Prothrombin rs1799963, MTHFR rs1801133) who also carry GG at rs11967262 may have compounded venous disease risk through convergent mechanisms.

Glutaryl-CoA dehydrogenase (GCDH) is a mitochondrial enzyme that breaks down three amino acids — lysine, hydroxylysine, and tryptophan — in the final steps of their catabolism. When GCDH fails, its substrates (glutaric acid and 3-hydroxyglutaric acid¹¹ 3-hydroxyglutaric acid
3-OHG is a potent endogenous neurotoxin that selectively injures the striatum during metabolic stress) accumulate and trigger striatal necrosis²² striatal necrosis
destruction of the caudate nucleus and putamen, the basal ganglia structures controlling voluntary movement, resulting in a severe dyskinetic movement disorder during encephalopathic crises.

The R402W variant (c.1204C>T, p.Arg402Trp) is the single most common pathogenic GCDH allele in European populations, accounting for approximately 40% of alleles in patients of German origin and 12-16% of Caucasian GA1 alleles across Europe. Haplotype analysis by Busquets et al.³³ Haplotype analysis by Busquets et al. demonstrated that all European R402W alleles trace back to a single ancestral founder mutation, explaining its unusual geographic concentration.

This is an autosomal recessive variant: one copy (CT genotype) produces an unaffected carrier; two copies or compound heterozygosity with another pathogenic GCDH allele causes glutaric acidemia type 1 (GA1).

The Mechanism

The c.1204C>T transition converts a coding-strand C to T, replacing arginine (a basic, positively charged residue) with tryptophan (bulky, aromatic) at position 402 of the mature GCDH protein — within the αDC (C-terminal alpha-helical) domain critical for subunit assembly. Keyser et al. 2008⁴⁴ Keyser et al. 2008 showed that the R402W protein is expressed at only 12% of wild-type signal intensity, undergoes rapid intramitochondrial degradation, and cannot form the functional GCDH homotetramer. The result is effectively complete loss of GCDH enzymatic activity.

Without functional GCDH, lysine catabolism stalls. Glutarylcarnitine accumulates in blood — the biomarker detected on newborn screening — while glutaric acid and 3-hydroxyglutaric acid build up in brain tissue. During any catabolic stress (febrile illness, fasting, surgery), the surge of these organic acids selectively injures the striatum⁵⁵ striatum
the basal ganglia nuclei (caudate, putamen, globus pallidus) that regulate movement, causing acute encephalopathic crises. If crises occur, the resulting dystonia is typically irreversible.

The biochemical phenotype of R402W is "high excretor" — R402W homozygotes produce large amounts of urinary glutaric acid, unlike some other GCDH alleles that cause low-excretor phenotypes where routine urine organic acid analysis may appear normal.

The Evidence

GA1 is an established autosomal recessive condition (OMIM 231670) with an estimated birth incidence of 1 in 30,000–100,000 live births. The R402W variant carries ClinVar classification of Pathogenic (Variation ID 2085, 2-star review status with criteria provided by multiple submitters) and is listed as OMIM allelic variant 608801.0004.

The impact of early detection is dramatic. Strauss et al. 2020⁶⁶ Strauss et al. 2020 followed 168 GA1 patients over 31 years: striatal degeneration occurred in 90% of unscreened patients, 47% of screened patients on protein restriction only, and just 7% of patients managed from birth with lysine-free formula plus emergency IV treatment during febrile episodes. The critical intervention window is the first six years of life — no neurological injuries occurred in the Strauss cohort after 19 months in the best-managed group.

A meta-analysis of 647 GA1 patients⁷⁷ meta-analysis of 647 GA1 patients by Boy et al. 2021 confirmed: 74.7% of newborn-screened patients remained asymptomatic versus only 9.6% of clinically diagnosed patients. Quality of therapy — adherence to the emergency protocol during febrile illness — was the strongest predictor of neurological outcome in the screened population.

Practical Actions

For carriers (CT genotype): no clinical management of GA1 is required. One functional GCDH allele is sufficient for adequate enzyme activity. The practical implication is reproductive: each child of two GCDH carriers has a 25% chance of inheriting two pathogenic alleles and developing GA1. Partner testing and genetic counseling are the key interventions.

For affected individuals (TT genotype, or CT compound heterozygous with another GA1 allele): confirmed GA1 requires immediate referral to a metabolic medicine specialist. The 2023 international guidelines⁸⁸ 2023 international guidelines specify a low-lysine diet (using lysine-free amino acid formula), L-carnitine supplementation (100 mg/kg/day in infants), and an emergency protocol authorizing IV glucose plus IV L-carnitine during any febrile episode. Dietary restriction is maintained strictly through age 6, then gradually relaxed as the striatum exits its vulnerability window.

Interactions

R402W most commonly causes GA1 as a homozygote (TT) or in compound heterozygosity with another pathogenic GCDH allele. The most clinically important compound heterozygous combination in European populations is R402W + R88C (rs142967670) — both alleles are independently classified Pathogenic in ClinVar, and compound heterozygotes have the same clinical syndrome as R402W homozygotes. Christensen et al. 2004⁹⁹ Christensen et al. 2004 confirmed no genotype-phenotype correlation for clinical outcome in GA1: crisis prevention, not which specific mutations are present, determines neurological prognosis.

Secondary carnitine deficiency occurs mechanistically in all untreated GA1: excess glutaric acid is conjugated to carnitine and excreted as glutarylcarnitine, depleting free carnitine needed for fatty acid oxidation. L-carnitine supplementation directly addresses this depletion, which is why it is part of the standard treatment regimen across all GA1 alleles.

The thyroid gland cannot make or release hormones on its own; it requires a continuous signal from the pituitary gland in the form of thyroid-stimulating hormone (TSH). TSH works by binding to its dedicated receptor — the TSH receptor (TSHR)¹¹ TSH receptor (TSHR)
a G protein-coupled receptor embedded in the membrane of thyroid follicular cells; its activation triggers a cascade that produces thyroxine (T4) and triiodothyronine (T3) — and triggering the intracellular machinery that produces thyroid hormones. When TSHR is non-functional, the pituitary sends ever-louder signals (elevated TSH) to a thyroid that cannot respond. The rs121908866 W546X variant replaces tryptophan at codon 546 with a premature stop signal, truncating the receptor protein and eliminating functional TSH signaling.

The Mechanism

The TSHR protein spans the cell membrane seven times — its extracellular loops bind TSH, and its transmembrane helices and intracellular loops relay the signal to adenylyl cyclase, triggering cAMP production. Tryptophan 546 sits in the fourth transmembrane domain, a critical structural region. The W546X stop-gain²² W546X stop-gain
creates the nonsense sequence TGG→TAG, introducing a premature termination codon that produces a severely truncated protein lacking the fifth, sixth, and seventh transmembrane helices, the third intracellular loop, and the entire C-terminal tail. Functional studies confirm that this truncated receptor cannot reach the cell surface and has negligible TSH binding activity. The result is complete TSH resistance: even massively elevated pituitary TSH output cannot drive thyroid hormone synthesis.

Because W546X is a null allele, the clinical phenotype follows a dose-response pattern determined by how many functional TSHR copies remain. Two W546X alleles (or one W546X combined with another inactivating mutation) leave the thyroid entirely unable to respond to TSH, producing severe congenital hypothyroidism. One W546X allele, with a working copy still present, allows partial receptor signaling — but the halved receptor density means the thyroid must work harder under higher TSH drive to maintain normal hormone output.

The Evidence

The clearest picture of W546X came from a Welsh neonatal screening study by Jordan et al. 2003³³ Welsh neonatal screening study by Jordan et al. 2003
W546X mutation of the thyrotropin receptor gene: potential major contributor to thyroid dysfunction in a Caucasian population. J Clin Endocrinol Metab, 88:1008–12. Two siblings detected through newborn screening were homozygous W546X and showed complete inability to respond to TSH. Screening of 368 euthyroid Welsh individuals identified two heterozygous carriers (G:A), giving an estimated heterozygous carrier frequency of approximately 1 in 180 in that Welsh population — substantially higher than the global gnomAD estimate of 0.03%, suggesting the mutation may be enriched in some European subpopulations.

In a compound heterozygosity study by Park et al. 2004⁴⁴ compound heterozygosity study by Park et al. 2004
Congenital hypothyroidism and apparent athyreosis with compound heterozygosity for inactivating TSHR mutations. Clin Endocrinol, 60:220–7, two siblings carried one W546X allele from their mother and one A553T allele from their father. The affected children had severe congenital hypothyroidism mimicking complete thyroid agenesis; the W546X-heterozygous mother had compensated hypothyroidism with thyroid hypoplasia. This family demonstrates the spectrum of TSHR inactivation: the severity scales with the degree of combined receptor loss.

Tenenbaum-Rakover et al. 2015⁵⁵ Tenenbaum-Rakover et al. 2015
Long-term outcome of loss-of-function mutations in thyrotropin receptor gene. Thyroid, 25:292–9 followed 94 subjects across 11 years and found that heterozygous TSHR mutation carriers showed only mild, stable TSH elevation without progression to overt hypothyroidism in most cases. Homozygous patients, however, showed declining free T4 levels over time, often requiring levothyroxine. This long-term natural history data supports periodic monitoring for heterozygous carriers rather than immediate treatment.

The reproductive significance stems from the well-established connection between maternal thyroid function and fertility, implantation, and early pregnancy. Subclinical hypothyroidism — defined as elevated TSH with normal free T4 — is associated with reduced conception rates, increased miscarriage risk, and impaired IVF outcomes in some (though not all) studies. Carriers of TSHR inactivating mutations who develop subclinical hypothyroidism are therefore a population in whom pre-conception TSH screening has particular clinical rationale.

Practical Actions

For heterozygous carriers, the key question is whether mild TSH elevation (common but not universal in this group) warrants treatment, particularly around pregnancy. Current endocrine guidelines recommend TSH < 2.5 mIU/L before and during the first trimester of pregnancy. A TSH above this threshold — whether from TSHR haploinsufficiency or other causes — may merit low-dose levothyroxine in the preconception period under specialist guidance. Crucially, TSH elevation from TSHR mutations is not autoimmune and does not reflect thyroid tissue destruction; thyroid antibodies (TPO-Ab, TG-Ab) will typically be negative, which is a useful diagnostic clue.

Homozygous carriers (extremely rare) require definitive endocrinology evaluation for congenital hypothyroidism management, which is beyond the scope of this entry.

Interactions

W546X in compound heterozygosity with other TSHR inactivating mutations (such as A553T, P162A, L467P, C600R, and others catalogued in OMIM 275200) produces phenotypes ranging from severe congenital hypothyroidism to compensated subclinical states depending on the combined residual receptor function. TSHR mutations do not interact with autoimmune thyroid genes such as CTLA4 (rs3087243) or PTPN22 (rs2476601) — the mechanism is structural, not immunological.

FOXO3 is the most consistently replicated longevity gene in humans — the only gene besides APOE whose protective associations have held across independent populations on multiple continents. Most research has focused on rs2802292 and related intronic variants, but the FOXO3 locus harbors a second layer of regulatory complexity. Flachsbart et al. 2017¹¹ Flachsbart et al. 2017
Identification and characterization of two functional variants in the human longevity gene FOXO3. Nat Commun. 2017 identified rs12206094 as one of two variants with direct experimental evidence for allele-specific function — making it one of the small number of FOXO3 longevity variants with a known molecular mechanism rather than a statistical association alone.

The T allele of rs12206094 is the longevity-associated minor allele, carried by approximately 30% of people globally. In a meta-analysis spanning three European longevity cohorts (German centenarians, French nonagenarians, and Danish oldest-old), each copy of the T allele was associated with a 22% increase in odds of exceptional longevity (OR = 1.219, p = 1.31×10⁻⁶). The effect was strongest in German centenarians aged 100–110 (OR = 1.306), where the T allele frequency climbed from 28.7% in controls to 34.5% in centenarians.

The Mechanism

rs12206094 sits in intron 2 of FOXO3, 94.5 kilobases from a second functional variant (rs4946935) in the same locus. The two variants are in moderate linkage disequilibrium (r² = 0.61), meaning they travel together on longevity haplotypes but can also be inherited independently — important context for understanding their additive but non-redundant effects.

The mechanistic story for rs12206094 centers on CTCF²² CTCF
CCCTC-binding factor, a master genome organizer that regulates chromatin looping, insulation of gene domains, and transcription factor access. Electrophoretic mobility shift assays showed that CTCF binds more strongly to the common C allele than to the longevity T allele. This is initially counterintuitive — a protective allele with weaker transcription factor binding — but the key insight is that CTCF at this site appears to act as an insulator or repressor rather than an activator. Reducing CTCF occupancy at the T allele may relieve local chromatin compaction, opening the locus to activating inputs.

Luciferase reporter assays in pancreatic and Jurkat T-cell lines confirmed that both alleles drive enhancer activity above baseline, but the T allele drives significantly greater promoter activity (p < 0.05). Critically, this enhanced activity is reversed by IGF-1 treatment — linking the variant directly to insulin/IGF-1 signaling (IIS), the most conserved longevity pathway from nematodes to humans. Under high-IGF-1 conditions (simulating caloric excess), the longevity allele's advantage is blunted; under low-IGF-1 conditions (caloric restriction or fasting), the T allele's enhanced enhancer activity drives higher FOXO3 expression.

eQTL data from multiple tissue databases confirmed the molecular phenotype: carriers of the T allele show higher FOXO3 mRNA expression across multiple tissues including brain regions, pancreas, prostate, and testis. This expression advantage translates into greater FOXO3 protein availability to activate downstream protective programs — antioxidant gene induction, DNA repair, autophagy, and attenuation of inflammatory signaling.

The Evidence

The Flachsbart 2017 study combined resequencing of the full FOXO3 locus with association testing in three independent European cohorts:

• German cohort: 717 long-lived individuals (≥95 years) vs. 1,111 controls; centenarian OR = 1.306 (p = 0.001), with stronger effects in males (OR = 1.469)
• French cohort: 536 individuals aged 91–115 years vs. 534 controls; OR = 1.160 (p = 0.008)
• Danish cohort: 1,088 individuals aged 92–101 years vs. 736 controls; OR = 1.235 (p = 0.012)
• Meta-analysis: OR = 1.219, p = 1.31×10⁻⁶ — well past genome-wide significance

Functional validation went beyond statistics. The CTCF binding difference was demonstrated in electrophoretic mobility shift assays (EMSAs) with nuclear extracts. Luciferase reporter assays used cells treated with and without IGF-1 to show the hormonal context-dependence. eQTL associations were confirmed in public databases spanning tens of thousands of tissue samples. This combination of population genetics, protein binding, reporter assays, and expression data meets the bar for a mechanistically characterized longevity variant.

The variant has since appeared in studies of other phenotypes — including noise-induced hearing loss and ankylosing spondylitis susceptibility — consistent with FOXO3's broad role in inflammation, oxidative stress response, and tissue homeostasis.

Practical Actions

The T allele's mechanism — blunted by high IGF-1, amplified by low IGF-1 — provides a clear dietary and lifestyle leverage point. Intermittent fasting, time-restricted eating, and low-glycemic diets all reduce circulating IGF-1, which may amplify the T allele's enhancer advantage. This is consistent with the broader literature showing that caloric restriction and IGF-1 pathway modulation extend lifespan in model organisms via FOXO3 activation.

For CT heterozygotes (42% of people), each T allele adds a partial boost to FOXO3 expression. The same lifestyle strategies that work for TT homozygotes apply, with proportionally smaller expected magnitude. For CC homozygotes, the protective variant is absent, but FOXO3 activation is still achievable through behavioral means — the gene responds to the same metabolic signals regardless of this variant's baseline effect.

Interactions

rs12206094 and rs4946935 are 94.5 kb apart with moderate LD (r² = 0.61) and operate through distinct molecular mechanisms — rs12206094 via CTCF binding dynamics, rs4946935 via SRF (serum response factor) binding. Carrying longevity alleles at both variants does not produce additive benefit; the Flachsbart study observed a negative epistatic interaction, suggesting the two regulatory elements share downstream effectors or compete for the same activating complexes.

rs2802292, the most studied FOXO3 longevity SNP in intron 2 (r² ≈ 0.00 with rs12206094), operates via a completely independent mechanism (HSF1 binding), making the FOXO3 locus a rare example of at least three functionally distinct longevity-associated regulatory elements in a single gene.

PPARGC1A¹¹ PPARGC1A
peroxisome proliferator-activated receptor gamma coactivator 1-alpha — the gene encoding PGC-1alpha, the master regulator of mitochondrial biogenesis sits at the center of how your body builds and maintains its energy-producing machinery. Every time you exercise aerobically, AMPK and calcium signaling activate PGC-1alpha, which then switches on hundreds of genes responsible for creating new mitochondria and optimizing their efficiency. More PGC-1alpha activity means more mitochondria, higher aerobic capacity, and greater metabolic resilience.

The rs12640088 variant is an intronic A-to-C substitution within PPARGC1A on chromosome 4. Unlike the well-studied Gly482Ser missense variant (rs8192678), which directly changes the PGC-1alpha protein sequence, rs12640088 sits in a non-coding intron. Intronic variants can still alter gene function through several mechanisms: modified splicing enhancer sequences, changes to intronic regulatory elements, or effects on mRNA secondary structure — any of which could subtly alter the amount or isoform balance of PGC-1alpha produced.

The Mechanism

The precise molecular mechanism by which rs12640088 affects PPARGC1A function has not been characterized in published functional studies. As an intron variant²² intron variant
a DNA change within a non-coding intervening sequence; can affect splicing, mRNA stability, or expression levels without changing the protein directly, it does not alter the amino acid sequence of PGC-1alpha. However, intronic regulatory variants in transcription factors and coactivators are a well-established class of functional polymorphism — the PPARGC1A promoter and intron 1 region in particular contains multiple regulatory elements that respond to exercise-induced signals including CREB binding sites, MEF2 elements, and histone acetylation marks.

The C allele is the minor allele, present at ~12% globally and ~13% in Europeans, with notably lower frequency in South Asian populations (~6%). Its consistent presence across populations suggests it is not strongly deleterious, but the frequency differential hints at possible population-specific selection pressures related to energy metabolism.

The Evidence

The direct evidence for rs12640088 is limited to three published studies, none of which examined exercise or aerobic fitness directly.

Type 2 diabetes and BMI interaction: The most substantive finding comes from a two-stage GWAS-based study of PPAR and PGC1 gene families³³ a two-stage GWAS-based study of PPAR and PGC1 gene families
Villegas et al. Genetic variation in the PPAR and PGC1 gene families and type 2 diabetes. Ann Hum Genet, 2014 in 6,075 Chinese participants. Among the SNPs tested, rs12640088 was the only one in PPARGC1A to show a statistically significant interaction with BMI in relation to type 2 diabetes risk. The study did not find a main-effect association, but the BMI interaction suggests that the variant's metabolic consequences are amplified or revealed by excess adiposity — consistent with PPARGC1A's known role in coupling energy surplus to mitochondrial adaptation and insulin sensitivity.

Liver disease null findings: Two Moroccan studies found no association between rs12640088 and either hepatitis C virus spontaneous clearance or fibrosis progression⁴⁴ hepatitis C virus spontaneous clearance or fibrosis progression
ElFihry et al. Virol Sin, 2020 or hepatocellular carcinoma susceptibility⁵⁵ hepatocellular carcinoma susceptibility
Tanouti et al. Asian Pac J Cancer Prev, 2023, suggesting the variant does not affect PPARGC1A's role in hepatic inflammation or carcinogenesis in these populations.

Practical Implications

Given that rs12640088 lies in PPARGC1A and shows a BMI-dependent interaction with metabolic risk, the most actionable implication for C allele carriers is maintaining healthy adiposity and supporting mitochondrial function — both of which directly modulate how this locus interacts with metabolic outcomes. The gene context suggests aerobic training and mitochondrial support nutrients remain relevant, though no exercise-specific studies have been performed for this variant.

The AA genotype (no C alleles) represents ~76% of the population and shows no evidence of altered risk. The AC heterozygote (~22%) and CC homozygote (~2%) carry one or two copies of the minor allele, with the rare CC genotype having the strongest potential effect.

Interactions

rs12640088 is located in the same gene as rs8192678 (Gly482Ser), the best-studied PPARGC1A variant. These two SNPs could theoretically compound if both reduce PPARGC1A expression or function — however, no study has examined their combined effect, and they are not in strong linkage disequilibrium given their distinct locations (coding exon vs. intron). The Villegas et al. study found rs12640088 was the only PPARGC1A SNP with a significant BMI interaction, distinct from rs8192678's direct fitness and metabolic associations.

The BCO1 gene (formerly called BCMO1) encodes beta-carotene oxygenase 1¹¹ beta-carotene oxygenase 1
The enzyme that cleaves beta-carotene at its central double bond, producing two molecules of retinal (vitamin A aldehyde), the sole enzyme responsible for converting dietary beta-carotene into retinal²² retinal
The aldehyde form of vitamin A, which is then converted to retinol (storage form) or retinoic acid (active signaling form), the body's usable form of vitamin A. The rs12934922 variant causes an arginine-to-serine substitution at position 267 of the protein (Arg267Ser), reducing the enzyme's catalytic efficiency. This is one of two common coding variants in BCO1 — the other being rs7501331 (Ala379Val)³³ rs7501331 (Ala379Val)
The other major BCO1 coding variant, located in exon 8, which independently reduces conversion by about 32% — that together explain much of the genetic basis for the "poor converter" phenotype seen in up to 45% of the population.

The Mechanism

BCO1 is an iron-dependent dioxygenase⁴⁴ dioxygenase
An enzyme that incorporates both atoms of molecular oxygen into the substrate, requiring iron as a cofactor that symmetrically cleaves beta-carotene at its central 15,15' double bond. The Arg267Ser substitution (A-to-T at rs12934922) occurs in the enzyme's catalytic domain and reduces its ability to process beta-carotene. In vitro studies⁵⁵ In vitro studies
Leung WC et al. Two common SNPs in the gene encoding beta-carotene 15,15'-monoxygenase alter beta-carotene metabolism in female volunteers. FASEB J, 2009 of the recombinant double mutant protein (267Ser + 379Val) showed a 57% reduction in catalytic activity compared to the wild-type enzyme. In human volunteers, carriers of both variant alleles demonstrated a 69% reduction in beta-carotene conversion, as measured by the retinyl palmitate to beta-carotene ratio in triglyceride-rich lipoproteins after a beta-carotene dose.

The consequence is straightforward: people with reduced BCO1 activity accumulate more beta-carotene in their blood (sometimes visibly, as carotenodermia⁶⁶ carotenodermia
A yellowish skin discoloration caused by elevated blood carotenoid levels, harmless but sometimes confused with jaundice) while producing less retinol. This matters most for individuals who rely heavily on plant-based sources for their vitamin A — a concern for vegans, vegetarians, and populations in regions where animal-source foods are scarce.

The Evidence

The foundational study by Leung and colleagues⁷⁷ Leung and colleagues
Leung WC et al. Two common SNPs in the gene encoding beta-carotene 15,15'-monoxygenase alter beta-carotene metabolism in female volunteers. FASEB J, 2009 identified rs12934922 (R267S) and rs7501331 (A379V) as the two common coding variants in BCO1, with variant allele frequencies of 42% and 24% respectively. Female volunteers carrying the 379Val allele alone showed a 32% reduction in conversion (P=0.005), while those carrying both 267Ser and 379Val had a 69% reduction (P=0.001). Fasting beta-carotene concentrations increased by 160% and 240% respectively in these groups, directly reflecting the impaired conversion.

A large study by Hendrickson and colleagues⁸⁸ Hendrickson and colleagues
Hendrickson SJ et al. BCO1 SNPs in relation to plasma carotenoid and retinol concentrations in women of European descent. Am J Clin Nutr, 2012 in 2,344 women of European descent confirmed that the rs12934922 T allele was associated with significantly higher plasma beta-carotene levels (P = 1.1 x 10^-12), with a 48% difference between extreme genotype score quintiles. Notably, the variant did not affect plasma retinol concentrations, which are tightly regulated by liver stores and only drop when deficiency is severe.

Population-level analysis by Lietz et al.⁹⁹ Lietz et al.
Lietz G et al. SNPs upstream from the beta-carotene 15,15'-monoxygenase gene influence provitamin A conversion efficiency in female volunteers. J Nutr, 2012 revealed large inter-ethnic differences in BCO1 variant frequencies, with European populations carrying the T allele at ~44% frequency compared to ~14% in African and East Asian populations. This means the poor converter phenotype is substantially more common in people of European ancestry.

Practical Implications

The most important question is whether you need to adjust your vitamin A sources based on this variant. For people with one or two T alleles:

• Plant sources alone may not suffice. Beta-carotene from sweet potatoes, carrots, and leafy greens is converted less efficiently, meaning you may need to eat substantially more to achieve the same retinol yield — or include preformed vitamin A sources.

• Preformed vitamin A (retinol) from animal sources — liver, egg yolks, dairy, fatty fish — bypasses BCO1 entirely. These become more important for carriers, especially TT homozygotes.

• Vegetarians and vegans with this variant should be especially aware. Without animal sources, supplementation with preformed retinol (retinyl palmitate or retinyl acetate) may be worth discussing with a healthcare provider.

• Cooking and fat improve beta-carotene bioavailability. Eating carotenoid-rich foods cooked (not raw) and with a source of fat maximizes what your BCO1 enzyme can process.

• Plasma retinol testing is not useful for detecting marginal deficiency because the liver buffers levels until stores are nearly depleted. A better approach is to track symptoms (night vision difficulty, dry skin, frequent infections) and ensure adequate dietary intake.

Interactions

The rs12934922 variant interacts directly with rs7501331 (BCO1 A379V), the other major coding variant in the same gene. The combined effect is more than additive: carriers of T alleles at both positions show 69% reduced conversion versus 32% for rs7501331 T carriers alone. This suggests that the two amino acid changes compound the structural disruption of the enzyme's catalytic site. Because both variants are common (42% and 24% T allele frequency respectively), a meaningful proportion of people — estimated at 7-10% of Europeans — carry risk alleles at both positions. For these individuals, preformed vitamin A is particularly important.

Upstream regulatory variants (rs6564851, rs11645428, rs6420424) also independently reduce BCO1 expression by 48-59% and may further compound the coding variant effects, though the interaction has not been formally quantified in a single study.

The PTPN22 gene encodes lymphoid tyrosine phosphatase (LYP), a critical negative regulator of T-cell receptor (TCR) signaling. While the well-known R620W coding variant¹¹ R620W coding variant
rs2476601, the strongest non-HLA autoimmune risk allele in Europeans, changes arginine to tryptophan at the protein level is the dominant PTPN22 risk variant in Europeans and absent from Asian populations, rs1310182 represents a distinct intronic variant in a putative transcription factor binding site²² putative transcription factor binding site
Intronic variants overlapping transcription factor binding sites can alter PTPN22 expression levels without changing the protein sequence that modulates PTPN22 expression rather than protein function. This variant fills a mechanistic gap: explaining PTPN22-associated autoimmune risk in populations where R620W is essentially absent.

The Mechanism

Unlike R620W, which alters the phosphatase protein's interaction with CSK kinase, rs1310182 (HGVS: NM_015967.7:c.2054-852T>C) is located deep within an intron, 852 nucleotides before exon 16. Its location within a transcription factor binding site³³ transcription factor binding site
Intronic enhancers and transcription factor binding sites can regulate mRNA production and splicing; rs1310182 overlaps a region also shared with the AP4B1 antisense RNA 1 gene suggests the variant influences PTPN22 transcript levels or splicing rather than amino acid sequence. PTPN22 expression is tightly regulated⁴⁴ tightly regulated
PTPN22 is subject to NFAT-dependent transcriptional induction after TCR stimulation, with 2.1–3.6× more transcript in memory and regulatory T cells versus naive T cells; even modest changes in this regulation can shift the threshold at which T cells activate against self-antigens. The functional consequence — altered immune tolerance — mirrors what is seen with R620W, but through a different molecular route.

PTPN22 is expressed predominantly in lymphoid tissue and acts as a negative regulator of TCR signaling by dephosphorylating LCK, FYN, ZAP70, and ITAMs of the TCRζ/CD3 complex. Changes in PTPN22 expression level rather than function can disrupt the delicate balance between effective immune surveillance and inappropriate self-attack.

The Evidence

Population specificity is the defining characteristic of rs1310182. The R620W variant (rs2476601) is essentially absent from East Asian populations (~1% allele frequency), yet PTPN22 haplotypes still show associations with autoimmune disease in these populations. A Japanese haplotype study⁵⁵ Japanese haplotype study
rs1310182 C allele frequency differed significantly between T1D patients and controls; susceptibility haplotype containing rs1310182 risk allele was enriched in T1D patients while protective haplotype was absent demonstrated that rs1310182 is the primary PTPN22 signal for type 1 diabetes in Japanese patients. A separate Japanese study found rs1310182-containing haplotypes associated with autoimmune thyroid disease⁶⁶ rs1310182-containing haplotypes associated with autoimmune thyroid disease
PTPN22 haplotype distribution significantly differed in AITD patients; involvement of PTPN22 locus rather than rs2476601 in AITD development in Japanese (both Graves' disease and Hashimoto's thyroiditis) independently of the R620W locus.

In an Armenian population study⁷⁷ Armenian population study
96 T1D patients vs 100 controls of Armenian descent; T allele OR 4.82, 95% CI 2.38–9.76; TC heterozygotes OR 2.39, 95% CI 1.35–4.24; CC genotype negatively associated with T1D of 96 T1D patients and 100 controls, rs1310182 showed striking association with T1D. The TT homozygote (AA on plus strand) was the primary risk state while TC heterozygotes (AG on plus strand) were at intermediate risk. The CC genotype (GG on plus strand) was negatively associated with T1D in Armenians — protective in that population context. Additionally, the GG (plus-strand) genotype associated with higher HbA1c⁸⁸ GG (plus-strand) genotype associated with higher HbA1c
HbA1c positively correlated with GG genotype at diagnosis and 12 months post-diagnosis in Armenian T1D patients at T1D diagnosis suggests an influence on metabolic control severity once disease is established.

In Europeans, rs1310182 was associated with RA independent of rs2476601⁹⁹ rs1310182 was associated with RA independent of rs2476601
Two PTPN22 SNPs on a haplotype distinct from the R620W haplotype contribute to RA risk independently in Caucasian populations, implying independent functional contributions at the PTPN22 locus.

However, a 2025 updated meta-analysis¹⁰¹⁰ 2025 updated meta-analysis
842 T1D cases and 801 controls across 6 studies; no significant pooled association for rs1310182 in any genetic model tested of T1D associations found no statistically significant pooled association for rs1310182, driven partly by conflicting directionality across populations: the risk allele in Armenians (A/T coding) is the protective allele in Japanese (where G/C coding is the risk allele). This conflicting directionality across populations argues for population-stratified interpretation rather than a single universal risk model.

Practical Implications

The clinical utility of rs1310182 is most relevant for East Asian individuals, where it captures autoimmune risk that rs2476601 does not. For individuals carrying the G allele (the risk allele in East Asian populations), awareness of elevated T1D and autoimmune thyroid disease risk is warranted — especially when combined with other autoimmune risk factors or family history. The HbA1c association in T1D patients suggests that this variant may also relate to glycemic control once disease is established.

For individuals with European or Armenian ancestry, interpretation is more nuanced due to conflicting allele directions. In those populations, the rs2476601 (R620W) variant remains the primary PTPN22 risk signal.

Interactions

Rs1310182 exists on the same haplotype background as other PTPN22 variants including rs2488457 (-1123G>C promoter), rs2476601 (R620W), and rs3789604. In Asian populations where R620W is absent or rare, rs1310182 acts as the primary PTPN22 risk signal. In European populations, rs1310182 may contribute independent risk¹¹¹¹ independent risk
Two SNPs on rs3811021/rs3789605 haplotype associated with RA independent of R620W beyond what rs2476601 alone captures. Combined haplotype analysis of the PTPN22 locus provides better risk stratification than any single variant alone.

For East Asian individuals, the combination of rs1310182-G with risk haplotypes containing rs2488457-C (the functional promoter variant -1123G>C) likely represents the primary PTPN22 autoimmune haplotype in those populations. These two SNPs capture complementary aspects of PTPN22 regulatory variation.

Under normal circumstances, pregnancy is one of the most vasodilatory states the human body can enter. Cardiac output rises by 40–50%, systemic vascular resistance falls, and blood pressure drops in the first trimester before gradually returning toward pre-pregnancy levels at term. Several molecular systems drive this extraordinary expansion of vascular capacity — and natriuretic peptides are among the most important. Atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), and C-type natriuretic peptide (CNP) all promote vasodilation, suppress the renin-angiotensin-aldosterone system, and facilitate sodium excretion. But a gene variant near NPR3 — the receptor that silently removes all three peptides from circulation — may blunt this protective effect precisely when it is needed most.

The Mechanism

The NPR3 gene¹¹ NPR3 gene
Natriuretic peptide receptor 3, also called NPR-C; located at chromosome 5p13.3; functions as a clearance receptor that binds ANP, BNP, and CNP with high affinity and removes them from circulation via receptor-mediated internalization and degradation encodes the dominant clearance mechanism for all three natriuretic peptides. Unlike NPR1 and NPR2 — which signal through intracellular guanylyl cyclase activity — NPR3 primarily acts as a "molecular sink," binding natriuretic peptides and internalizing them for degradation. When NPR3 is more highly expressed or more active, natriuretic peptides are cleared faster, their circulating half-life shortens, and their vasodilatory effects are attenuated.

The rs13154066 variant lies in a regulatory region approximately 40 kb upstream of the NPR3 transcription start site. Analogous blood pressure-associated NPR3 locus SNPs²² blood pressure-associated NPR3 locus SNPs
As shown for the rs1173771 block — blood pressure-elevating alleles reduce NPR3 mRNA in vascular smooth muscle cells via altered chromatin accessibility (Leach et al., Hum Mol Genet 2017, PMID 29016846) have been shown to modulate NPR3 transcript levels: alleles that increase blood pressure correspond to reduced NPR3 expression in vascular smooth muscle, but this apparently paradoxical finding reflects the complexity of the clearance receptor system — reduced NPR3-mediated clearance increases natriuretic peptide half-life, and its net effect on blood pressure can depend on which target tissue and which natriuretic peptide dominate in a given physiologic context. In pregnancy, the relevant signaling context shifts substantially: CNP acts on uterine smooth muscle and spiral arteries³³ CNP acts on uterine smooth muscle and spiral arteries
CNP stimulates endometrial decidualization, promotes trophoblast invasion, and mediates spiral artery remodeling via NPR2 signaling that is tightly regulated by NPR3-mediated clearance, and impaired CNP signaling is mechanistically linked to defective spiral artery remodeling — a central pathologic feature of preeclampsia.

Direct molecular evidence links NPR3 dysregulation to preeclampsia: one study found that NPR-A was absent and NPR-C was upregulated in maternal vessel endothelium from preeclamptic women⁴⁴ NPR-A was absent and NPR-C was upregulated in maternal vessel endothelium from preeclamptic women
Compared to normotensive pregnancies where NPR-C was undetectable in maternal vessels; n=12 tissue samples (6 preeclamptic, 6 normotensive) (Gu et al., Pregnancy Hypertens 2018, PMID 29523263), suggesting that in preeclampsia the balance tips toward clearance and away from productive natriuretic peptide signaling — precisely the opposite of what is needed for blood pressure control during pregnancy.

The Evidence

The strongest evidence for this SNP comes from a landmark multi-ancestry genome-wide association study of hypertensive disorders of pregnancy⁵⁵ multi-ancestry genome-wide association study of hypertensive disorders of pregnancy
Honigberg et al., Nature Medicine 2023; tested 20,064 preeclampsia cases and 703,117 controls, and 11,027 gestational hypertension cases and 412,788 controls; multi-ancestry discovery and replication cohorts that identified rs13154066 as the lead variant at a new locus (5p13) specifically associated with gestational hypertension. Each additional C allele was associated with an approximately 11% higher odds of gestational hypertension (OR 1.11, p=4.5×10⁻¹⁰). Colocalization analysis and polygenic priority scores in this study independently nominated NPR3 as the most likely causal gene at this locus — not a nearby bystander gene.

The causal direction was confirmed in a two-sample Mendelian randomization⁶⁶ two-sample Mendelian randomization
Harpe et al. Int J Hypertension 2025; used 12 NPR3 SNPs as instruments from female-specific UK Biobank data (n=198,402); outcome from 296,824-person preeclampsia GWAS: genetically proxied reduced NPR3 function was associated with a 54% lower odds of preeclampsia (OR 0.46, 95% CI 0.30–0.69). Because reduced NPR3 function means slower natriuretic peptide clearance and therefore higher circulating ANP/BNP/CNP levels, this finding is consistent with the hypothesis that natriuretic peptide signaling is protective in pregnancy hypertension.

A NPR3 missense variant rs2270915 (N521D) has been separately associated with diastolic dysfunction (OR 1.94, p=0.03) in 1,931 randomly selected adults⁷⁷ diastolic dysfunction (OR 1.94, p=0.03) in 1,931 randomly selected adults
Pereira et al., PLOS ONE 2014; G/G homozygotes showed 43% diastolic dysfunction prevalence vs 28% in A/A+A/G genotypes and with blood pressure in two independent diabetic cohorts⁸⁸ blood pressure in two independent diabetic cohorts
Saulnier et al., Diabetes Care 2011; AA homozygotes had ~2.5 mmHg lower SBP than G carriers and greater reduction with dietary salt restriction. These functional associations reinforce that NPR3 genetic variation has real physiologic consequences for cardiovascular regulation — and by extension, for the cardiovascular demands of pregnancy.

Practical Implications

Carriers of the CC genotype at rs13154066 may have modestly higher NPR3-driven natriuretic peptide clearance, attenuating the vasodilatory protection these peptides normally provide during pregnancy. The variant is common (~60% C allele frequency globally), meaning the vast majority of the population carries at least one C allele — its population impact on gestational hypertension risk is therefore substantial even though the per-person OR of 1.11 is modest.

For carriers of CT or CC genotypes, the actionable focus centers on blood pressure surveillance during pregnancy and awareness of gestational hypertension symptoms. Where natriuretic peptide signaling is relevant to clinical decision-making — such as in interpreting BNP or NT-proBNP levels — this genotype may provide useful context. The variant does not currently trigger changes in standard preeclampsia prevention protocols (low-dose aspirin is recommended based on clinical risk factors), but knowing one's genotype can inform both personal vigilance and conversations with prenatal care providers.

Interactions

PLCE1 rs932764 (phospholipase C epsilon 1): Both NPR3 rs13154066 and PLCE1 rs932764 were identified as independent preeclampsia-associated loci in the same Honigberg 2023 multi-ancestry GWAS, and PLCE1 was additionally identified in the multitrait analysis. NPR3 disrupts natriuretic peptide clearance (a blood pressure and vascular tone pathway), while PLCE1 mutations cause nephrotic syndrome and affect podocyte integrity and glomerular filtration — a second pathway that converges on the proteinuria-hypertension axis central to preeclampsia. Individuals carrying risk alleles at both loci may have dual vulnerability: impaired vasodilatory signaling from the NPR3 side and glomerular dysfunction susceptibility from the PLCE1 side, representing two independent pathophysiologic routes to the same clinical syndrome. Proposed compound action: rs13154066 CC + rs932764 risk genotype — "Dual Preeclampsia Risk: NPR3-Mediated Vascular and PLCE1-Mediated Renal Vulnerability." Action type: monitoring. Evidence level: moderate.

NPR3 rs2270915 (N521D missense): This separate NPR3 coding variant is associated with diastolic dysfunction and blood pressure, providing a functional layer of NPR3 impairment that compounds the regulatory effect of rs13154066. Individuals carrying risk alleles at both NPR3 loci (the GWAS regulatory variant and the N521D coding variant) may experience additive impairment of natriuretic peptide clearance efficiency and cardiac pressure-volume regulation. These two variants are in the same gene but appear to operate through distinct mechanisms (regulatory expression vs. protein function), and their combined effect on pregnancy blood pressure has not been formally studied.

The TRAF3IP2 locus on chromosome 6q21 encodes both the Act1 adaptor protein (TRAF3IP2) and an antisense long noncoding RNA (TRAF3IP2-AS1) that acts as a molecular rheostat controlling how much Act1 protein the cell produces. rs13210247 sits inside an intron of TRAF3IP2 but overlaps the TRAF3IP2-AS1 transcript — making it a regulatory variant that fine-tunes the entire IL-17 signaling axis from a position that traditional coding-variant analysis would overlook. The G allele (also designated A4165G in TRAF3IP2-AS1 numbering) was identified as part of the TRAF3IP2 psoriasis susceptibility locus in a landmark 2010 GWAS and has since been shown to carry independent mechanistic weight as a gain-of-function lncRNA variant.

The Mechanism

Act1 is the essential adaptor for IL-17 receptor signaling¹¹ essential adaptor for IL-17 receptor signaling
Act1 couples the cytoplasmic domain of the IL-17RA/IL-17RC receptor complex to TRAF6, driving NF-κB activation and inflammatory gene expression in keratinocytes, fibroblasts, and mucosal epithelium; it is also required for normal keratinocyte differentiation through the AP1 pathway. The gene sits on the minus strand, and overlapping it is TRAF3IP2-AS1, an antisense lncRNA on the plus strand. This lncRNA recruits SRSF10²² SRSF10
Serine/arginine-rich splicing factor 10, a splicing regulator that modulates IRF1 mRNA processing and expression levels when bound to TRAF3IP2-AS1, which then downregulates IRF1 — a transcription factor that drives Act1 expression. More TRAF3IP2-AS1 activity → more SRSF10 recruitment → less IRF1 → less Act1.

The rs13210247 G allele is a gain-of-function mutant³³ rs13210247 G allele is a gain-of-function mutant
In functional assays, the G variant of TRAF3IP2-AS1 shows enhanced ability to recruit SRSF10 compared to the A wild-type, amplifying suppression of the IRF1-Act1 transcriptional axis; treatment with the mouse lncRNA homolog or SRSF10 had therapeutic effects in mouse psoriasis and autoimmune encephalomyelitis models. This enhanced SRSF10 binding → reduced IRF1 → reduced Act1 expression.

How does reducing Act1 increase psoriasis risk? Act1 has a dual role in keratinocyte biology⁴⁴ dual role in keratinocyte biology
Act1/TRAF3IP2 silencing decreases early differentiation markers (KRT1, KRT10, DSC1, DSG1) while increasing late differentiation genes (SPRR2, LCE3) characteristic of psoriatic lesions; this occurs through elevated FosB and Fra1 nuclear expression via AP1 binding sites, independently of the IL-17 pathway; the authors note this paradox remains an active area of investigation. Reducing Act1 disrupts the normal keratinocyte differentiation program through AP1 pathway deregulation, producing a psoriasis-like transcriptional signature. Separately, the missense variant rs33980500 on the same haplotype disrupts Act1's TRAF6-binding domain — so two independent mechanisms (reduced Act1 quantity via rs13210247, and altered Act1 quality via rs33980500) converge on the same locus.

The Evidence

Two independent GWAS published simultaneously in Nature Genetics in 2010 established TRAF3IP2 as a major psoriasis susceptibility locus. Ellinghaus et al.⁵⁵ Ellinghaus et al.
6,487 psoriasis cases and 8,037 controls across German, Swedish, and American cohorts; combined P=2.36×10⁻¹⁰ for rs13210247 identified rs13210247 with an odds ratio of 1.69 (95% CI 1.48–1.94) for psoriasis. Huffmeier et al.⁶⁶ Huffmeier et al.
Discovery cohort of 609 German psoriatic arthritis cases + 990 controls, replicated across six European and North American cohorts confirmed rs13210247 in moderate LD (r²=0.63) with the missense variant rs33980500 — but the two SNPs are on partially distinct haplotype blocks separated by ~9.5 kb, meaning they capture overlapping but not identical disease signal.

The haplotype analysis is where rs13210247's contribution becomes clearest. A four-SNP haplotype carrying rs13196377_G + rs13190932_G + rs33980500_T + rs13210247_A carries an OR of 2.7 (P=0.0054) for psoriasis⁷⁷ OR of 2.7 (P=0.0054) for psoriasis
Haplotype analysis in independent psoriasis cohort following initial GWAS; this is the primary risk haplotype at the TRAF3IP2 locus. A second risk haplotype (rs13196377_A + rs13190932_A + rs33980500_T + rs13210247_G) carries OR=1.8 — rs33980500_T is the shared element conferring risk across both haplotypes, while rs13210247 alleles differ between the two, reflecting two distinct haplotype backgrounds at this locus.

Disease associations extend across the IL-17/autoimmune spectrum. In Chinese cohorts, rs13210247 G is strongly associated with Behçet's disease (OR=2.40, P=6.9×10⁻⁸) and Vogt-Koyanagi-Harada syndrome (OR=2.07, P=7.2×10⁻⁶)⁸⁸ rs13210247 G is strongly associated with Behçet's disease (OR=2.40, P=6.9×10⁻⁸) and Vogt-Koyanagi-Harada syndrome (OR=2.07, P=7.2×10⁻⁶)
Study of 610 BD patients, 721 VKH patients, and 1,591 controls; AG genotype frequency 11.6% in BD vs 4.8% in controls; both conditions share Th17/IL-17 pathway dysregulation with psoriasis. In autoimmune thyroid disease, the AG genotype shows significant association with both Graves' disease and Hashimoto's thyroiditis (https://pubmed.ncbi.nlm.nih.gov/40440802/⁹⁹ https://pubmed.ncbi.nlm.nih.gov/40440802/), extending the locus's relevance beyond skin and mucosa to the endocrine-immune interface.

Practical Implications

rs13210247 sits on the highest-risk psoriasis haplotype at the TRAF3IP2 locus. For carriers who also carry rs33980500_T (D10N), the combined haplotype represents the maximum TRAF3IP2 contribution to psoriatic disease risk — both the quantity of Act1 (reduced by the lncRNA variant) and the quality of Act1 signaling (disrupted TRAF6 binding) are simultaneously compromised.

The breadth of autoimmune associations (psoriasis, psoriatic arthritis, Behçet's disease, VKH syndrome, autoimmune thyroid disease) reflects the centrality of IL-17/Act1 signaling across multiple organ systems. G allele carriers should be aware that autoimmune risk is not organ-specific: a personal or family history of any IL-17-driven condition warrants vigilance across this spectrum.

Known psoriasis triggers that activate Th17 pathways deserve attention: streptococcal pharyngitis, skin trauma (Koebner phenomenon), and psoriasis-precipitating medications (beta-blockers, lithium, antimalarials, interferons). The lncRNA therapeutic angle identified by He et al. is scientifically interesting but not yet clinically actionable.

Interactions

rs13210247 is in moderate LD (r²=0.63) with rs33980500 (D10N), but the two variants are distinct — they co-occur on the high-risk haplotype but also segregate independently. rs13210247 operates at the transcriptional level (Act1 quantity via TRAF3IP2-AS1/SRSF10/IRF1), while rs33980500 operates at the protein level (Act1 TRAF6-binding capacity). Together they represent the two main disease-contributing mechanisms at this locus.

rs13196377 and rs13190932 are the other members of the four-SNP haplotype but appear to be tagging variants rather than functional drivers — they do not independently reproduce the functional effects of D10N or rs13210247.

rs12191877 (HLA-C¹⁰¹⁰ rs12191877 (HLA-C
tags HLA-Cw*0602, the dominant psoriasis susceptibility allele affecting T-cell immune tolerance) creates a dual-hit with TRAF3IP2 rs13210247: impaired self-tolerance (HLA) combined with reduced Act1 regulatory capacity. Because HLA-Cw6 is also a major predictor of biologic therapy response, combined carriers face both elevated disease risk and a pharmacogenomically distinct treatment profile.